Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences (Nasdaq: PCRX) announced positive topline results from a Phase 3 study of EXPAREL for postsurgical pain management after knee arthroplasty. The study demonstrated a statistically significant reduction in cumulative pain scores and opioid consumption through 96 hours compared to bupivacaine HCl (p<0.01). Following these results, Pacira plans to submit a supplemental New Drug Application to expand the EXPAREL label to include a femoral nerve block indication. The drug was well tolerated, reinforcing its position in opioid-sparing pain management.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $50.2 million for July 2022, driven by its flagship product EXPAREL, which achieved average daily sales of 105% compared to July 2021. EXPAREL generated $40.9 million in sales, while ZILRETTA and iovera° contributed $8.2 million and $1.1 million respectively. Despite challenges from COVID-19 affecting elective procedures, the company reported ongoing growth and plans to enhance customer training and partnerships to support product adoption.
Pacira BioSciences, Inc. (Nasdaq: PCRX) and the NFL Alumni Association have announced a partnership aimed at raising awareness for non-opioid pain management strategies.
The collaboration will educate retired players and youth sports organizations on effective alternatives to opioids for managing pain, particularly postsurgical pain and knee osteoarthritis. The program will unfold through events and educational content shared via NFLA channels through May 2025, focusing on player safety and combatting the opioid crisis.
This partnership highlights Pacira's commitment to redefining opioid use in pain management.
Pacira BioSciences (PCRX) reported a strong second quarter of 2022 with total revenues of $169.4 million, a 25% increase year-over-year, attributed to successful integration of Flexion. EXPAREL net sales were $137 million, contributing significantly to net income of $19.9 million or $0.44 per share. Adjusted EBITDA stood at $44.9 million. The company completed patient enrollment in two Phase 3 studies for EXPAREL, which may expand its indications. However, ongoing challenges related to COVID-19 could impact future revenue guidance.
TAMPA, Fla., Aug. 02, 2022 – Pacira BioSciences (NASDAQ: PCRX) will participate in the analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Aug. 10, 2022, at 11:30 AM ET. Investors can access the live audio on the company’s website, with a replay available for two weeks post-event. Pacira is focused on non-opioid treatments, marketing products like EXPAREL®, ZILRETTA®, and ioveraº®. The company's mission aims to redefine opioid use, addressing chronic pain and related conditions.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its Q2 financial results on August 3, 2022, before U.S. market opens. Following the report, a conference call is scheduled at 8:30 a.m. ET. The call can be accessed by dialing 1-800-715-9871 (US) or 1-646-307-1963 (international), using passcode 9287305. Interested investors can join via webcast on Pacira's investor page. The company focuses on non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at reducing opioid reliance in pain management.
Pacira BioSciences reported preliminary revenues of $169.4 million for Q2 2022, up from $135.6 million in Q2 2021. Sales were driven by EXPAREL and ZILRETTA, with average daily sales of EXPAREL at 105% of the prior year for Q2. The company is focused on expanding its portfolio of non-opioid pain management solutions. Despite pandemic disruptions, they are optimistic about growth, especially in outpatient settings. The company remains cautious about future guidance due to ongoing challenges, including labor shortages and potential COVID-19 impacts.
Pacira BioSciences and the National Safety Council announced their partnership to launch the Connect2Prevent program, aimed at educating employees and their families on preventing opioid misuse and addiction. The program features a 10-12 week curriculum addressing the risks of opioids, stigma, and alternatives to pain management. This initiative, which starts piloting this summer, encourages meaningful discussions about substance use. Key data highlights the serious risks, such as a 33% higher chance of misuse for those using opioids before high school.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for May 2022, with EXPAREL achieving $44.9 million, a 9% increase from $41.2 million in May 2021. Average daily sales for EXPAREL reached 104% of the prior year, reflecting an increase in utilization. Iovera° sales rose slightly to $1.1 million. CEO Dave Stack highlighted EXPAREL's growth amid ongoing pandemic challenges and noted robust performance of ZILRETTA with over 220 new accounts. The company currently refrains from providing 2022 revenue guidance due to uncertainties from COVID-19 and elective surgery recovery.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 9:00 AM ET in New York. The live audio of the event can be accessed via the company's website, and a replay will be available for two weeks thereafter.
Pacira is dedicated to providing non-opioid treatment options, including three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº. The company aims to redefine opioid usage and address chronic pain and other debilitating conditions.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
